PMID: 26795027Jan 23, 2016Paper

Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoblasts and Adipocytes and its Role in Treatment of Osteoporosis

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
Cheng WangYu Wang

Abstract

Osteoporosis is a systemic metabolic bone disorder characterized by a decrease in bone mass and degradation of the bone microstructure, leaving bones that are fragile and prone to fracture. Most osteoporosis treatments improve symptoms, but to date there is no quick and effective therapy. Bone marrow mesenchymal stem cells (BMMSCs) have pluripotent potential. In adults, BMMSCs differentiate mainly into osteoblasts and adipocytes in the skeleton. However, if this differentiation is unbalanced, it may lead to a decrease in bone mass. If the number of adipocyte cells increases and that of osteoblast cells decreases, osteoporosis can result. A variety of hormones and cytokines play an important role in the regulation of BMMSCs bidirectional differentiation. Therefore, a greater understanding of the regulation mechanism of BMMSC differentiation may provide new methods to prevent and treat osteoporosis. In addition, autologous, allogeneic BMMSCs or genetically modified BMMSC transplantation can effectively increase bone mass and density, increase bone mechanical strength, correct the imbalance in bone metabolism, and increase bone formation, and is expected to provide a new strategy and method for the treatment of osteoporosis.

Citations

Jun 5, 2020·MSphere·Enakshi RoySt Patrick Reid
Aug 14, 2018·Okajimas Folia Anatomica Japonica·Rieko AsaumiIwao Sato
Jan 25, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yage TianDongfeng Chen
Sep 26, 2019·Frontiers in Bioengineering and Biotechnology·Christiane Laranjo SalgadoFernando Jorge Mendes Monteiro
Oct 5, 2019·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·João H LopesCelso A Bertran
Oct 28, 2017·BMC Musculoskeletal Disorders·Xia ChenYongde Peng
Aug 26, 2018·Clinical and Experimental Pharmacology & Physiology·Paweł ŁęgoszPaweł Małdyk
Oct 18, 2018·Evidence-based Complementary and Alternative Medicine : ECAM·Aofei YangZhanghua Li
Jul 10, 2019·Stem Cells International·Vasilis Paspaliaris, George Kolios
Apr 14, 2016·Anatomical Science International·Yukino KamigakiTakashi Yosue
Feb 20, 2018·Experimental and Therapeutic Medicine·Zhixiong YanJiahui Wang
Aug 1, 2018·European Journal of Clinical Investigation·María Correa-RodríguezBlanca Rueda-Medina
Feb 28, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Anja Saalbach, Ulf Anderegg
Jan 18, 2020·International Journal of Molecular Sciences·Abdul QadirAirong Qian
Nov 14, 2019·Cytotechnology·Nadia S MahmoudMohamed A Tantawy
Nov 8, 2018·International Journal of Molecular Sciences·Chiara ArgentatiSabata Martino
Nov 24, 2020·Stem Cell Research & Therapy·Parisa KangariMahboobeh Razmkhah
Jan 26, 2021·Journal of Cellular Physiology·Dimitrios Agas, Maria Giovanna Sabbieti
Jan 28, 2021·The Kaohsiung Journal of Medical Sciences·Qi JiangXiong-Wen Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2022 Meta ULC. All rights reserved